00:38 , Jul 19, 2019 |  BC Innovations  |  Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

Two years in, GammaDelta says the $100 million Takeda option deal it signed months after launching gave the company a boost that would have been hard to come by any other way. Build-to-buy deal structures...
21:25 , May 1, 2019 |  BC Extra  |  Company News

Management tracks: Gilead, bluebird, Apollomics

Gilead Sciences Inc. (NASDAQ:GILD) said Robin Washington will retire as EVP and CFO, effective March 1, 2020. Washington, who joined Gilead in 2008, will continue in her role while the company identifies a successor. Gene...
21:18 , Jan 9, 2019 |  BC Extra  |  Company News

Management tracks: Tak joins Flagship, Evercore taps Mehrotra

Paul-Peter Tak has stepped down from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to join Flagship Pioneering as a venture partner. He was GSK's SVP of R&D, chief immunology officer and development lead. Evercore ISI hired Ravi Mehrotra...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
17:58 , Jul 20, 2018 |  BC Week In Review  |  Company News

Kite looks to Gadeta for gamma delta T cell tech

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
20:06 , Jul 19, 2018 |  BC Extra  |  Company News

Kite, Gadeta in gamma delta T cell deal

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
00:06 , Jun 28, 2018 |  BC Extra  |  Company News

Management tracks: Arrakis, Astellas

Arrakis Therapeutics Inc. (Waltham, Mass.) founder and CSO Russ Petter is transitioning to Jennifer Petter. The news was announced in a blog post by Chairman and CEO Michael Gilman. "The support for this transition at...
18:21 , May 25, 2018 |  BC Week In Review  |  Financial News

Lava raises €16M for gamma delta T cell platform

Lava Therapeutics B.V. ('s-Hertogenbosch, the Netherlands) raised €16 million ($18.8 million) on May 23 in a series B round led by Gilde Healthcare and Versant Ventures. Also participating were MRL Ventures Fund, Lupus Ventures and...
09:12 , May 23, 2018 |  BC Extra  |  Financial News

Lava raises €16M for gamma delta T cell platform

Lava Therapeutics B.V. ('s-Hertogenbosch, the Netherlands) raised €16 million ($18.8 million) in a series B round led by Gilde Healthcare and Versant Ventures. Also participating were MRL Ventures Fund, Lupus Ventures and Biox Biosciences. Lupus...